[8-K] Boyd Gaming Corporation Reports Material Event
On 7/22/25 Unity Biotechnology (UBX) entered into a Purchase Agreement with President/Secretary and sole director Craig R. Jalbert to sell a single Series A Preferred Share for $1. The share carries 600,000,000 votes but may be used only on the forthcoming Dissolution Proposal and must mirror the proportion of votes actually cast by common shareholders. It is non-convertible, pays a $0.01 priority dividend and automatically transfers back to the company after the stockholder meeting.
The step is designed to neutralise abstentions and broker non-votes, effectively lowering the practical approval hurdle for the board-approved dissolution plan announced 6/27/25. UBX鈥檚 common stock was suspended from Nasdaq on 7/9/25 and now trades on OTC Pink (UNBX); a Form 25 will be filed to delist. The issuance was made under the 搂4(a)(2) private-placement exemption. This 8-K/A otherwise only adds the former address to the cover page.
Il 22/07/25 Unity Biotechnology (UBX) ha stipulato un Accordo di Acquisto con il Presidente/Segretario e unico direttore Craig R. Jalbert per vendere una singola Azione Preferenziale di Serie A per $1. L'azione conferisce 600.000.000 voti ma pu貌 essere utilizzata solo per la prossima Proposta di Scioglimento e deve rispecchiare la proporzione dei voti effettivamente espressi dagli azionisti ordinari. Non 猫 convertibile, paga un dividendo prioritario di $0,01 e si trasferisce automaticamente alla societ脿 dopo l'assemblea degli azionisti.
Questa mossa 猫 pensata per neutralizzare le astensioni e i voti non espressi dai broker, abbassando di fatto la soglia pratica di approvazione per il piano di scioglimento approvato dal consiglio e annunciato il 27/06/25. Le azioni ordinarie di UBX sono state sospese dal Nasdaq il 09/07/25 e ora vengono negoziate su OTC Pink (UNBX); sar脿 presentato un modulo Form 25 per la cancellazione dalla quotazione. L'emissione 猫 stata effettuata sotto l'esenzione per collocamento privato 搂4(a)(2). Questo 8-K/A aggiunge altrimenti solo il vecchio indirizzo nella pagina di copertina.
El 22/07/25 Unity Biotechnology (UBX) firm贸 un Acuerdo de Compra con el Presidente/Secretario y 煤nico director Craig R. Jalbert para vender una 煤nica Acci贸n Preferente Serie A por $1. La acci贸n otorga 600.000.000 votos pero solo puede usarse exclusivamente en la pr贸xima Propuesta de Disoluci贸n y debe reflejar la proporci贸n de votos realmente emitidos por los accionistas comunes. No es convertible, paga un dividendo prioritario de $0.01 y se transfiere autom谩ticamente de vuelta a la compa帽铆a tras la reuni贸n de accionistas.
Esta medida est谩 dise帽ada para neutralizar las abstenciones y los votos no emitidos por los corredores, reduciendo efectivamente el umbral pr谩ctico de aprobaci贸n para el plan de disoluci贸n aprobado por la junta y anunciado el 27/06/25. Las acciones comunes de UBX fueron suspendidas del Nasdaq el 09/07/25 y ahora se negocian en OTC Pink (UNBX); se presentar谩 un Formulario 25 para su exclusi贸n. La emisi贸n se realiz贸 bajo la exenci贸n de colocaci贸n privada 搂4(a)(2). Este 8-K/A solo a帽ade adem谩s la direcci贸n anterior en la portada.
2025雲� 7鞗� 22鞚�, Unity Biotechnology(UBX)電� 靷灔/牍勳劀鞚挫瀽 鞙犾澕頃� 鞚挫偓鞚� Craig R. Jalbert鞕� 雼澕 鞁滊Μ歃� A 鞖办劆欤茧ゼ 1雼煬鞐� 韺愲Г頃橂姅 毵るГ瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 6鞏� 響�鞚� 鞚橁舶甓岇潉 臧�歆�歆�毵�, 雼り皜鞓る姅 頃挫偘 鞝滌晥鞐� 鞓れ 靷毄霅� 靾� 鞛堨溂氅�, 氤错喌欤� 欤检＜霌れ澊 鞁れ牅搿� 頄夓偓頃� 韴憸 牍勳湪鞚� 氚橃榿頃挫暭 頃╇媹雼�. 鞝勴櫂 攵堦皜電ロ晿氅� 鞖办劆 氚半嫻旮堨溂搿� 0.01雼煬毳� 歆�旮夗晿瓿� 欤检＜齑濏殞 頉� 鞛愲彊鞙茧 須岇偓搿� 氚橅櫂霅╇媹雼�.
鞚� 臁办箻電� 旮瓣秾 氚� 欷戧皽鞚� 氙疙埇響滊ゼ 欷戫檾頃橃棳, 2025雲� 6鞗� 27鞚� 氚滍憸霅� 鞚挫偓須� 鞀轨澑 頃挫偘 瓿勴殟鞚� 鞁れ鞝侅澑 鞀轨澑 旮办鞚� 雮稊旮� 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�. UBX鞚� 氤错喌欤茧姅 2025雲� 7鞗� 9鞚� 雮橃姢雼レ棎靹� 瓯半灅臧� 鞝曥霅橃棃鞙茧┌ 順勳灛 OTC Pink(UNBX)鞐愳劀 瓯半灅霅橁碃 鞛堨姷雼堧嫟; 靸侅灔 韽愳毳� 鞙勴暅 Form 25臧� 鞝滌稖霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 氚滍枆鞚� 搂4(a)(2) 靷爜 氚办箻 氅挫牅鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�. 鞚� 8-K/A 氍胳劀電� 響滌鞐� 鞚挫爠 欤检唽毵� 於旉皜搿� 旮办灛頃╇媹雼�.
Le 22/07/25, Unity Biotechnology (UBX) a conclu un accord d'achat avec le pr茅sident/secr茅taire et unique administrateur Craig R. Jalbert pour vendre une seule action privil茅gi茅e de s茅rie A pour 1 $. L'action conf猫re 600 000 000 voix mais ne peut 锚tre utilis茅e qu'脿 l'occasion de la prochaine proposition de dissolution et doit refl茅ter la proportion des voix effectivement exprim茅es par les actionnaires ordinaires. Elle n'est pas convertible, verse un dividende prioritaire de 0,01 $ et est automatiquement transf茅r茅e 脿 la soci茅t茅 apr猫s l'assembl茅e g茅n茅rale des actionnaires.
Cette mesure vise 脿 neutraliser les abstentions et les votes non exprim茅s par les courtiers, r茅duisant ainsi efficacement le seuil pratique d'approbation du plan de dissolution approuv茅 par le conseil et annonc茅 le 27/06/25. Les actions ordinaires d'UBX ont 茅t茅 suspendues du Nasdaq le 09/07/25 et se n茅gocient d茅sormais sur OTC Pink (UNBX) ; un formulaire 25 sera d茅pos茅 pour la radiation. L'茅mission a 茅t茅 r茅alis茅e sous l'exemption de placement priv茅 搂4(a)(2). Ce 8-K/A ajoute par ailleurs uniquement l'ancienne adresse en page de couverture.
Am 22.07.25 schloss Unity Biotechnology (UBX) eine Kaufvereinbarung mit Pr盲sident/Sekret盲r und alleinigem Direktor Craig R. Jalbert ab, um eine einzelne Series A Preferred Share f眉r 1 $ zu verkaufen. Die Aktie tr盲gt 600.000.000 Stimmen, darf jedoch nur f眉r den bevorstehenden Aufl枚sungsantrag verwendet werden und muss das Verh盲ltnis der tats盲chlich von den Stammaktion盲ren abgegebenen Stimmen widerspiegeln. Sie ist nicht wandelbar, zahlt eine vorrangige Dividende von 0,01 $ und wird nach der Hauptversammlung automatisch an das Unternehmen zur眉ck眉bertragen.
Dieser Schritt soll Enthaltungen und Nichtstimmen von Brokern neutralisieren und senkt effektiv die praktische Zustimmungsschwelle f眉r den vom Vorstand genehmigten Aufl枚sungsplan, der am 27.06.25 angek眉ndigt wurde. Die Stammaktien von UBX wurden am 09.07.25 vom Nasdaq ausgesetzt und werden jetzt im OTC Pink (UNBX) gehandelt; ein Formular 25 zur Delistung wird eingereicht. Die Ausgabe erfolgte unter der 搂4(a)(2) Privatplatzierungs-Ausnahme. Dieses 8-K/A f眉gt ansonsten nur die fr眉here Adresse auf der Titelseite hinzu.
- Proportional voting mechanism reduces risk that abstentions block the board-approved dissolution, providing procedural certainty.
- Automatic retirement of the Series A share after the vote prevents long-term dilution or control issues.
- Planned dissolution indicates termination of operations and uncertain recovery for shareholders.
- Nasdaq suspension and pending delisting move trading to OTC Pink, reducing liquidity and institutional interest.
- Concentration of voting power in a single insider may raise governance and fairness concerns.
Insights
TL;DR: High-vote preferred share helps ensure dissolution passes; governance and value outlook remain negative.
The issuance of a single Series A share with 600 MM votes is a classic proportional voting device that removes the blocking power of abstentions. While technically fair鈥攂ecause it mirrors ballots actually cast鈥攊t materially shifts the effective threshold, making it easier for management to secure stockholder approval of liquidation. Investors gain no economic benefit: the share is non-convertible, non-participating in liquidation and reverts post-vote. Combined with the recent delisting to OTC Pink, the filing underscores that UBX no longer pursues an operating strategy, only an orderly wind-down. Risk of little or no residual value remains high.
TL;DR: Filing formalises wind-down mechanics; impact is decisive but value-destructive.
By locking in 600 MM proportional votes, the board almost guarantees approval of the pending Plan of Dissolution, accelerating the liquidation timetable. For creditors, faster execution may limit administrative burn; for equity holders, upside is capped鈥攖here are no dividend, conversion or liquidation rights attached to the preferred. The $1 issuance price and automatic retirement demonstrate the vote-only purpose. However, shifting to OTC and delisting signal diminished marketability, and liquidation usually yields cents on the dollar. I view the development as materially negative for ordinary shareholders.
Il 22/07/25 Unity Biotechnology (UBX) ha stipulato un Accordo di Acquisto con il Presidente/Segretario e unico direttore Craig R. Jalbert per vendere una singola Azione Preferenziale di Serie A per $1. L'azione conferisce 600.000.000 voti ma pu貌 essere utilizzata solo per la prossima Proposta di Scioglimento e deve rispecchiare la proporzione dei voti effettivamente espressi dagli azionisti ordinari. Non 猫 convertibile, paga un dividendo prioritario di $0,01 e si trasferisce automaticamente alla societ脿 dopo l'assemblea degli azionisti.
Questa mossa 猫 pensata per neutralizzare le astensioni e i voti non espressi dai broker, abbassando di fatto la soglia pratica di approvazione per il piano di scioglimento approvato dal consiglio e annunciato il 27/06/25. Le azioni ordinarie di UBX sono state sospese dal Nasdaq il 09/07/25 e ora vengono negoziate su OTC Pink (UNBX); sar脿 presentato un modulo Form 25 per la cancellazione dalla quotazione. L'emissione 猫 stata effettuata sotto l'esenzione per collocamento privato 搂4(a)(2). Questo 8-K/A aggiunge altrimenti solo il vecchio indirizzo nella pagina di copertina.
El 22/07/25 Unity Biotechnology (UBX) firm贸 un Acuerdo de Compra con el Presidente/Secretario y 煤nico director Craig R. Jalbert para vender una 煤nica Acci贸n Preferente Serie A por $1. La acci贸n otorga 600.000.000 votos pero solo puede usarse exclusivamente en la pr贸xima Propuesta de Disoluci贸n y debe reflejar la proporci贸n de votos realmente emitidos por los accionistas comunes. No es convertible, paga un dividendo prioritario de $0.01 y se transfiere autom谩ticamente de vuelta a la compa帽铆a tras la reuni贸n de accionistas.
Esta medida est谩 dise帽ada para neutralizar las abstenciones y los votos no emitidos por los corredores, reduciendo efectivamente el umbral pr谩ctico de aprobaci贸n para el plan de disoluci贸n aprobado por la junta y anunciado el 27/06/25. Las acciones comunes de UBX fueron suspendidas del Nasdaq el 09/07/25 y ahora se negocian en OTC Pink (UNBX); se presentar谩 un Formulario 25 para su exclusi贸n. La emisi贸n se realiz贸 bajo la exenci贸n de colocaci贸n privada 搂4(a)(2). Este 8-K/A solo a帽ade adem谩s la direcci贸n anterior en la portada.
2025雲� 7鞗� 22鞚�, Unity Biotechnology(UBX)電� 靷灔/牍勳劀鞚挫瀽 鞙犾澕頃� 鞚挫偓鞚� Craig R. Jalbert鞕� 雼澕 鞁滊Μ歃� A 鞖办劆欤茧ゼ 1雼煬鞐� 韺愲Г頃橂姅 毵るГ瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 6鞏� 響�鞚� 鞚橁舶甓岇潉 臧�歆�歆�毵�, 雼り皜鞓る姅 頃挫偘 鞝滌晥鞐� 鞓れ 靷毄霅� 靾� 鞛堨溂氅�, 氤错喌欤� 欤检＜霌れ澊 鞁れ牅搿� 頄夓偓頃� 韴憸 牍勳湪鞚� 氚橃榿頃挫暭 頃╇媹雼�. 鞝勴櫂 攵堦皜電ロ晿氅� 鞖办劆 氚半嫻旮堨溂搿� 0.01雼煬毳� 歆�旮夗晿瓿� 欤检＜齑濏殞 頉� 鞛愲彊鞙茧 須岇偓搿� 氚橅櫂霅╇媹雼�.
鞚� 臁办箻電� 旮瓣秾 氚� 欷戧皽鞚� 氙疙埇響滊ゼ 欷戫檾頃橃棳, 2025雲� 6鞗� 27鞚� 氚滍憸霅� 鞚挫偓須� 鞀轨澑 頃挫偘 瓿勴殟鞚� 鞁れ鞝侅澑 鞀轨澑 旮办鞚� 雮稊旮� 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�. UBX鞚� 氤错喌欤茧姅 2025雲� 7鞗� 9鞚� 雮橃姢雼レ棎靹� 瓯半灅臧� 鞝曥霅橃棃鞙茧┌ 順勳灛 OTC Pink(UNBX)鞐愳劀 瓯半灅霅橁碃 鞛堨姷雼堧嫟; 靸侅灔 韽愳毳� 鞙勴暅 Form 25臧� 鞝滌稖霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 氚滍枆鞚� 搂4(a)(2) 靷爜 氚办箻 氅挫牅鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�. 鞚� 8-K/A 氍胳劀電� 響滌鞐� 鞚挫爠 欤检唽毵� 於旉皜搿� 旮办灛頃╇媹雼�.
Le 22/07/25, Unity Biotechnology (UBX) a conclu un accord d'achat avec le pr茅sident/secr茅taire et unique administrateur Craig R. Jalbert pour vendre une seule action privil茅gi茅e de s茅rie A pour 1 $. L'action conf猫re 600 000 000 voix mais ne peut 锚tre utilis茅e qu'脿 l'occasion de la prochaine proposition de dissolution et doit refl茅ter la proportion des voix effectivement exprim茅es par les actionnaires ordinaires. Elle n'est pas convertible, verse un dividende prioritaire de 0,01 $ et est automatiquement transf茅r茅e 脿 la soci茅t茅 apr猫s l'assembl茅e g茅n茅rale des actionnaires.
Cette mesure vise 脿 neutraliser les abstentions et les votes non exprim茅s par les courtiers, r茅duisant ainsi efficacement le seuil pratique d'approbation du plan de dissolution approuv茅 par le conseil et annonc茅 le 27/06/25. Les actions ordinaires d'UBX ont 茅t茅 suspendues du Nasdaq le 09/07/25 et se n茅gocient d茅sormais sur OTC Pink (UNBX) ; un formulaire 25 sera d茅pos茅 pour la radiation. L'茅mission a 茅t茅 r茅alis茅e sous l'exemption de placement priv茅 搂4(a)(2). Ce 8-K/A ajoute par ailleurs uniquement l'ancienne adresse en page de couverture.
Am 22.07.25 schloss Unity Biotechnology (UBX) eine Kaufvereinbarung mit Pr盲sident/Sekret盲r und alleinigem Direktor Craig R. Jalbert ab, um eine einzelne Series A Preferred Share f眉r 1 $ zu verkaufen. Die Aktie tr盲gt 600.000.000 Stimmen, darf jedoch nur f眉r den bevorstehenden Aufl枚sungsantrag verwendet werden und muss das Verh盲ltnis der tats盲chlich von den Stammaktion盲ren abgegebenen Stimmen widerspiegeln. Sie ist nicht wandelbar, zahlt eine vorrangige Dividende von 0,01 $ und wird nach der Hauptversammlung automatisch an das Unternehmen zur眉ck眉bertragen.
Dieser Schritt soll Enthaltungen und Nichtstimmen von Brokern neutralisieren und senkt effektiv die praktische Zustimmungsschwelle f眉r den vom Vorstand genehmigten Aufl枚sungsplan, der am 27.06.25 angek眉ndigt wurde. Die Stammaktien von UBX wurden am 09.07.25 vom Nasdaq ausgesetzt und werden jetzt im OTC Pink (UNBX) gehandelt; ein Formular 25 zur Delistung wird eingereicht. Die Ausgabe erfolgte unter der 搂4(a)(2) Privatplatzierungs-Ausnahme. Dieses 8-K/A f眉gt ansonsten nur die fr眉here Adresse auf der Titelseite hinzu.
|
|
|
|
||
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated July 24, 2025
|
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
Date:
|
July 24, 2025
|
Boyd Gaming Corporation
|
|
By:
|
/s/ Lori M. Nelson
|
|
|
Lori M. Nelson
|
||
|
Senior Vice President Financial Operations and Reporting and Chief Accounting Officer
|
||
Source:
FAQ
Why did Unity Biotechnology (UBX) issue only one Series A Preferred Share?
How will the Series A Preferred Share affect the dissolution vote for UBX?
What happens to the Series A Preferred Share after the UBX stockholder meeting?
Why was UBX delisted from Nasdaq?
Does the Series A Preferred Share receive liquidation proceeds?
